Research and Development

PharmaTher is focused on the research and development of psychedelic pharmaceuticals for FDA approval by finding new uses and drug combinations with panaceAI™ our artificial intelligence drug repurposing platform, novel delivery systems.  We are building our product pipeline that targets disorders of the brain and nervous system, which will benefit from the attractive regulatory incentives for expedited approvals, such as the FDA 505(b)(2) regulatory pathway and orphan drug, fast track and breakthrough designations.

Discovery

Artificial Intelligence for new uses of psychedelics and combinations with FDA drugs

Development

R&D in combining psychedelics with FDA approved drugs

Delivery

Novel microneedle delivery system for psychedelics

Over $100 Billion Global Market Potential

Mental Illness

970

Million People
​Global Prevalence
Potential Indications Depression, Anxiety, Substance Abuse, Bipolar, Schizophrenia, PTSD

Neuropsychiatric

970

Million People 
​Global Prevalence
Potential Indications
​Depression, Anxiety, Substance Abuse, Bipolar, Schizophrenia, PTSD

Neurological

$800

Billion
Cost Burden in the U.S.
Potential Indications Parkinson's, Epilepsy, Alzheimer, Dementia, Multiple Sclerosis, ALS (Lou Gerhig's Disease)

Neurological

$800

Billion
Cost Burden in the U.S.
Potential Indications
Parkinson's, Epilepsy, Alzheimer, Dementia, Multiple Sclerosis
​

Neuromuscular

90

Percent
Agree to be a an unmet need
Potential Indications Amyotrophic lateral sclerosis, Duchenne muscular dystrophy​
​

Pain

85%

of people claim to suffer from both body and head pain
Potential Indications
Post-operative,
Neuropathic pain,
Acute and Chronic pain

Connect With Us

PharmaTher Holdings Ltd.
82 Richmond Street East
Toronto, Ontario  Canada
M5C 1P1